Asia · Prensa financiera · SCMP Business
Akeso shares plummet as Chinese firm’s cancer drug ivonescimab faces FDA setback

Resumen detallado
Shares in Hong Kong-listed Akeso plunged as much as 31.8 per cent on Monday morning after the US Food and Drug Administration (FDA) rejected its cancer drug application, raising…
MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.scmp.com)

